Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 117

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 117
---
 psychosocial
therapy, naltrexone could reduce alcohol cravings and decrease relapse rates in alcoholics.

The FDA approved the use of naltrexone to treat
AUD in 1994. DuPont then renamed the drug Revia.

Campral (acamprosate) is the most recent medication
approved for the treatment of alcohol dependence or alcoholism in the U. S. It works by normalizing alcohol related changes in the brain,
reducing some of the extended physical distress and emotional discomfort people can experience when they quit drinking (also known as
post-acute withdrawal syndrome) that can lead to relapse.

In 1982, the French company Laboratoires Meram
developed acamprosate for the treatment of alcohol dependence. It was tested for safety and efficacy from 1982 until 1988 when it was
authorized for use by the French government to treat alcoholism. It was first marketed under the name Aotal.

For more than 20 years, acamprosate was widely
used throughout Europe for treating people with AUD. It was not approved for use in the United States until July 2004. It was first marketed
in the United States in January 2005 under the brand name Campral. Campral is currently marketed in the United States by Forest Pharmaceuticals.

These therapies suffer from a number of limitations,
including high relapse rates, inconvenient treatment regimens, difficult access and an inability to maintain abstinence after medically
assisted withdrawal.

Buprenorphine, methadone and naltrexone are used
as maintenance therapy with the primary goal of preventing relapse while naloxone is used as rescue therapy for opioid overdose. Access
to treatments such as buprenorphine and methadone is limited by their treatment regimens and inherent risks of abuse, placing significant
requirements and regulations on practitioners. In addition to these limitations, current treatment options are not considered to be highly
effective; approximately 75% of patients undergoing Opioids Use Disorder, or OUD, therapy experience relapse within one year of treatment.
For abuse of other substances, such as cocaine or methamphetamine, no pharmacological agents have been approved for treatment.

Despite the limitations of current treatment options
for AUD, we believe that very few psychedelic treatment candidates are being developed to address this problem.

Weight loss, Obesity, and Metabolic Syndrome

The prevalence of obesity has reached epidemic
proportions, with approximately one billion people